Promising phase 2B trial results of Lanifibranor in NASH

NASH Webinar Series

Webinar 2 - Promising phase 2B trial results of Lanifibranor in NASH

Topic:

In this webinar Prof. Sven Francque will be discussing the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.

Speaker: Prof. Sven Francque

Host: Dr. Manuel Castro Cabezas

Co-host: Prof. Christophe Moreno

------------------------------------------------------------------------------------------

Audience: Clinicians, researchers, pharmaceutical industry workers, public health workers

NASH Webinar Series

This webinar is the second webinar of the NASH webinar series, each focusing on recent developments or publications on nonalcoholic steatohepatitis (NASH). The topics and publications are selected by KOLs of NASH Clinical based on relevant ground-breaking NASH research in a high-impact journal. During these webinars we offer you the opportunity to interact with original authors and experts in the NASH field.